Cempra, Inc. (CEMP)

[agamemnus]

The fact is that BP messes up rollouts ALL THE TIME. Arna and Eisai was a major blunder. They are not better.

And once again -- big pharma doesn't want to take the risk on a FQ. They'd demand too much premium. Big pharma is cautious as a rule. So they'd either buy the company or not do anything. They wouldn't do a partnership. So you're left with Eisai and co. which are not going to be any better than hiring your own salesforce.

You stated last year that having a sales force before approval is a major blunder. Well, it is. But now you say that 50 (to start) isn't enough. But they can't train a lot of salespeople that quickly (apparently). The strategy makes 100% sense.